Unnamed: 0 float64 0 392 ⌀ | Ticker stringclasses 2
values | Year stringclasses 6
values | Text stringlengths 4 2.74k | Embedding stringlengths 9 34.5k |
|---|---|---|---|---|
null | Ticker | Year | Text | Embedding |
0 | JNJ | 2016 | Johnson & Johnson and its subsidiaries (the "Company") have approximately 127,100 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. Johnson & Johnson is a holding company, which has more than 250 operating companies conducting busine... | [-0.004641624633222818, 0.015090003609657288, -0.02204299345612526, -0.007053758017718792, -0.02245866134762764, 0.023617492988705635, -0.0003306449216324836, 0.03360611945390701, -0.019536390900611877, 0.0008675492717884481, -0.014422415755689144, 0.01229999028146267, -0.015102599747478962, -0.005882330238819122, 0.00... |
1 | JNJ | 2016 | The Executive Committee of Johnson & Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Company's three business segments: Consumer, Pharmaceutical and Medical Devices. Within th... | [-0.0031034264247864485, 0.0010064729722216725, -0.02277246117591858, -0.015276418998837471, -0.02954474836587906, 0.017615700140595436, 0.007547739893198013, 0.029596446081995964, -0.008277958258986473, -0.001979019958525896, -0.010778793133795261, 0.0027673968579620123, -0.008930630050599575, 0.009208501316606998, -0... |
2 | JNJ | 2016 | The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. Additional information required by this item is incorporated herein by reference to the narrative and tabular descriptions of segments and operating results under: Item 7 “Management’s Discussion and Analysis of Results... | [-0.009805739857256413, 0.007062966004014015, -0.006586521398276091, -0.028380632400512695, -0.022843576967716217, 0.017023228108882904, -0.006168023217469454, -0.004767662845551968, -0.007204611320048571, -0.010063277557492256, 0.001167771639302373, 0.04736114665865898, -0.008872167207300663, 0.003766485955566168, -0.... |
3 | JNJ | 2016 | The Consumer segment includes a broad range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets. Baby Care includes the JOHNSON’S® line of products. Oral Care includes the LISTERINE® product line. Major brands in Skin Care include the AVEENO®; ... | [0.02203509211540222, 0.020356744527816772, -0.01855657994747162, -0.026880647987127304, -0.026230964809656143, 0.010022718459367752, 0.020302604883909225, 0.011477738618850708, -0.005911441519856453, -0.01258084736764431, 0.0031181415542960167, 0.012032676488161087, -0.03616570681333542, 0.0009043118334375322, -0.0042... |
4 | JNJ | 2016 | The Pharmaceutical segment is focused on five therapeutic areas: immunology (e.g., rheumatoid arthritis, inflammatory bowel disease and psoriasis), infectious diseases and vaccines (e.g., HIV, hepatitis, respiratory infections and tuberculosis), neuroscience (e.g., Alzheimer's disease, mood disorders and schizophrenia)... | [0.0112451808527112, -0.0006597435567528009, -0.008113861083984375, -0.013680651783943176, -0.030853677541017532, 0.020166488364338875, -0.009735319763422012, -0.009334878996014595, -0.005789988208562136, -0.016897311434149742, 0.029619529843330383, 0.015807585790753365, 0.0025733280926942825, -0.011534024029970169, -0... |
5 | JNJ | 2016 | schizophrenia and the maintenance treatment of Bipolar 1 Disorder in adults; VELCADE® (bortezomib), a treatment for multiple myeloma and for use in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma; ZYTIGA® (abirat... | [-0.027450673282146454, -0.01880553737282753, 0.022526057437062263, -0.01788555458188057, -0.005712689366191626, 0.03149589151144028, -0.020401978865265846, -0.007312512956559658, -0.00628429651260376, -0.0029595044907182455, -0.002029374474659562, 0.014016213826835155, 0.007819856517016888, 0.014936196617782116, -0.01... |
6 | JNJ | 2016 | The Medical Devices segment includes a broad range of products used in the orthopaedic, surgery, cardiovascular, diabetes care and vision care fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care profes... | [-0.0004484902892727405, 0.0027830915059894323, -0.004859420005232096, -0.016651205718517303, -0.00017267510702367872, 0.02453719638288021, -0.00118526560254395, -0.001425362192094326, -0.002536231651902199, -0.02091207541525364, 0.003743477864190936, 0.032599031925201416, -0.023279225453734398, -0.006381158716976643, ... |
7 | JNJ | 2016 | The business of Johnson & Johnson is conducted by more than 250 operating companies located in 60 countries, including the U.S., in virtually all countries throughout the world. The products made and sold in the international business include many of those described above under “– Segments of Business – Consumer,” “– P... | [0.002715866081416607, 0.012530378066003323, -0.017442388460040092, -0.0025035403668880463, -0.013424047268927097, 0.01803816668689251, 0.0029456212650984526, 0.02755795791745186, -0.002132762921974063, -0.010540221817791462, -0.021498756483197212, 0.03833268955349922, -0.03569604828953743, -0.007783158682286739, 0.003... |
8 | JNJ | 2016 | Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S. activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties. | [0.0021267312113195658, -0.052988532930612564, 0.013959755189716816, -0.04224830120801926, -0.015652231872081757, 0.007698862347751856, -0.022345788776874542, 0.0030238714534789324, 0.018337290734052658, -0.013514366932213306, -0.016772067174315453, 0.018464544788002968, -0.00768613675609231, 0.006788996979594231, 0.01... |
9 | JNJ | 2016 | Raw materials essential to the Company's business are generally readily available from multiple sources. Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company. | [-0.01570758782327175, -0.02176622860133648, -0.016644762828946114, -0.016987955197691917, -0.02962002344429493, 0.006910018622875214, -0.023086193948984146, -0.027824869379401207, 0.004141391254961491, -0.01524560060352087, 0.015588791109621525, 0.01565478928387165, -0.009021962992846966, -0.003169566858559847, -0.010... |
10 | JNJ | 2016 | The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own or are licensed under a number of patents relating to their products and manufacturing processes, which in the aggregate are believed to be of material importance to the Company in the... | [-0.009441955015063286, 0.006142918486148119, 0.00469772145152092, -0.02867802605032921, 0.006737608462572098, -0.007395422551780939, -0.02272447943687439, -0.007441934663802385, -0.0071030608378350735, -0.013780868612229824, 0.020292561501264572, 0.008146260865032673, 0.024691276252269745, 0.0029900630470365286, 0.001... |
11 | JNJ | 2016 | There are two sets of patents related specifically to REMICADE® (infliximab). The first set of patents is co-owned by Janssen Biotech, Inc., a wholly-owned subsidiary of Johnson & Johnson, and NYU Langone Medical Center (NYU). Janssen Biotech, Inc. has an exclusive license to NYU's interests in the patents. These paten... | [-0.030560296028852463, 0.007146954070776701, -0.004648478701710701, -0.038765814155340195, -0.008731513284146786, 0.0030573445837944746, -0.02286762371659279, -0.011177388951182365, -0.030770694836974144, -0.0071732536889612675, 0.023143770173192024, -0.003274317365139723, 0.027825122699141502, -0.001339642913080752, ... |
12 | JNJ | 2016 | The second set of patents specifically related to REMICADE® was granted to The Kennedy Institute of Rheumatology in Europe, Canada, Australia and the United States. Janssen Biotech, Inc. has licenses (exclusive for human anti-TNF antibodies and semi-exclusive for non-human anti-TNF antibodies) to these patents that exp... | [-0.02253965474665165, -0.001348366029560566, 0.001001689932309091, -0.03871025890111923, -0.004802891053259373, 0.018702562898397446, -0.022304730489850044, -0.004822468385100365, -0.03197576850652695, 0.005860049277544022, 0.015922628343105316, -0.00922729354351759, 0.027433905750513077, -0.02533264085650444, 0.00681... |
13 | JNJ | 2016 | States and 2018 in the United States. The validity of these patents has been challenged. Certain claims have been invalidated and others are under review in various patent offices around the world and are also subject to litigation in Canada. | [-0.0035129678435623646, -0.029592342674732208, -0.004167438484728336, -0.02897637151181698, -0.004908530507236719, 0.0032883945386856794, -0.023137465119361877, -0.003429554868489504, -0.03100394643843174, -0.01161364745348692, 0.002621091203764081, -7.128196739358827e-05, -0.006987437605857849, -0.015027161687612534,... |
14 | JNJ | 2016 | The Company does not expect that any additional extensions will be available for the above described patents specifically related to REMICADE®. If any of the REMICADE® related patents discussed above is found to be invalid, any such patent could not be relied upon to prevent the introduction of biosimilar versions of R... | [-0.0243032556027174, 0.006552607752382755, 0.010972886346280575, -0.03666016831994057, 0.00596323749050498, 0.015919625759124756, -0.020978940650820732, -0.020687567070126534, -0.025866080075502396, -0.0036322439555078745, 0.015919625759124756, -0.006214878521859646, 0.015681227669119835, -0.01715134270489216, -2.1095... |
15 | JNJ | 2016 | In addition to competing in the immunology market with REMICADE®, the Company is currently marketing STELARA® (ustekinumab), SIMPONI® (golimumab) and SIMPONI ARIA® (golimumab), next generation immunology products with remaining patent lives of up to eight years. | [-0.007678363472223282, -0.006748354993760586, 0.007473165635019541, -0.027774494141340256, -0.005977208726108074, 0.015899507328867912, -0.04464041814208031, 0.0005158900166861713, -0.019394487142562866, -0.0114116370677948, 0.01200737152248621, 0.01646876521408558, 0.008988980203866959, -0.005801797844469547, 0.00829... |
16 | JNJ | 2016 | The Company’s subsidiaries have made a practice of selling their products under trademarks and of obtaining protection for these trademarks by all available means. These trademarks are protected by registration in the United States and other countries where such products are marketed. The Company considers these tradem... | [-0.01752183586359024, -0.028833726420998573, 0.008954173885285854, -0.02708154357969761, -0.006007026415318251, 0.011337658390402794, 0.000938899873290211, 0.014210724271833897, 0.02295875921845436, -0.017238395288586617, -0.015280071645975113, 0.013373283669352531, 0.0031597281340509653, -0.000614391581621021, -0.009... |
17 | JNJ | 2016 | Worldwide sales do not reflect any significant degree of seasonality; however, spending has been heavier in the fourth quarter of each year than in other quarters. This reflects increased spending decisions, principally for advertising and research and development activity. | [-1.0398570339020807e-05, -0.026065943762660027, 0.00937209464609623, -0.027899479493498802, -0.007408476434648037, -0.014123182743787766, -0.003989179618656635, -0.0013844434870406985, -0.009737562388181686, -0.015461168251931667, 0.023736856877803802, 0.033548753708601, -0.013144470751285553, 0.0011358940973877907, -... |
18 | JNJ | 2016 | In all of their product lines, the Company's subsidiaries compete with companies both locally and globally. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, both internally and externally sourced, involving the development and th... | [-0.009604181163012981, -0.0058346218429505825, 0.007689900696277618, -0.013203290291130543, -0.009754963219165802, 0.030680932104587555, 0.013295071199536324, 0.013183623552322388, -0.004251406993716955, -0.021791329607367516, -0.006155853625386953, 0.019273919984698296, 0.001144798705354333, -0.01439643744379282, -0.... |
19 | JNJ | 2016 | Research activities represent a significant part of the Company’s businesses. Research and development expenditures relate to the processes of discovering, testing and developing new products, improving existing products, as well as demonstrating product efficacy and regulatory compliance prior to launch. The Company r... | [-0.0030528914649039507, -0.012282376177608967, 0.0030754220206290483, -0.025337228551506996, -0.00296276924200356, 0.008677486330270767, 0.00841999426484108, 0.012333874590694904, 0.002988518448546529, -0.0005870016757398844, -0.0016149586299434304, 0.029070865362882614, -0.015346533618867397, -0.006173374596983194, -... |
20 | JNJ | 2016 | The Company is subject to a variety of U.S. and international environmental protection measures. The Company believes that its operations comply in all material respects with applicable environmental laws and regulations. The Company’s compliance with these requirements did not change during the past year, and is not e... | [-0.009003289975225925, -0.029021311551332474, -0.017415357753634453, -0.014664887450635433, -0.012049371376633644, 0.015860185027122498, -0.0025191218592226505, -0.02141253650188446, -0.013039026409387589, -0.00845705159008503, 0.007942945696413517, -0.0013414965942502022, -0.008187145926058292, 0.0034284477587789297,... |
21 | JNJ | 2016 | The Company’s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation. In the U.S., the drug, device and cosmetic industries have long been subject to regulation by various federal and stat... | [0.010274333879351616, -0.01126714888960123, -0.008896148763597012, -0.017713917419314384, -0.015467019751667976, 0.013442198745906353, -0.008099284023046494, 0.025578061118721962, -0.009686482138931751, -0.016342265531420708, 0.024532992392778397, -0.004199870862066746, -0.0064402371644973755, -0.0005662150797434151, ... |
22 | JNJ | 2016 | FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction. Similar trends are also evident in major markets outside of the U.S. | [0.015131893567740917, -0.009997622109949589, 0.005524132400751114, -0.01834329031407833, -0.007076968438923359, -0.008735530078411102, -0.0026084345299750566, 0.026272667571902275, -0.02262515388429165, -0.002593566896393895, 0.009733309969305992, -0.0010869853431358933, 0.005583602469414473, -0.00618491368368268, -0.... |
23 | JNJ | 2016 | The costs of human health care have been and continue to be a subject of study, investigation and regulation by governmental agencies and legislative bodies around the world. In the U.S., attention has been focused on drug prices and profits and programs that encourage doctors to write prescriptions for particular drug... | [0.010146682150661945, -0.005318351089954376, 0.010087880305945873, -0.033060021698474884, 0.018346352502703667, 0.004838131368160248, 0.0172225721180439, 0.01818954572081566, -0.030943134799599648, -0.002489302074536681, -0.0027359453961253166, 0.018633829429745674, 0.0051256101578474045, 0.006775344256311655, -0.0089... |
24 | JNJ | 2016 | U.S. government agencies continue to implement the extensive requirements of the Patient Protection and Affordable Care Act (the "ACA"). These have both positive and negative impacts on the U.S. healthcare industry with much remaining uncertain as to how various provisions of the ACA will ultimately affect the industry... | [-0.007933996617794037, -0.010170294903218746, 0.022311124950647354, -0.04760397970676422, -0.010332345962524414, 0.0033220371697098017, -0.013625213876366615, 0.02254447713494301, -0.035910408943891525, -0.008089565671980381, 0.01489568967372179, -0.0054740686900913715, 0.021987024694681168, 0.00034597801277413964, -0... |
25 | JNJ | 2016 | The regulatory agencies under whose purview the Company operates have administrative powers that may subject it to actions such as product withdrawals, recalls, seizure of products and other civil and criminal sanctions. In some cases, the Company’s subsidiaries may deem it advisable to initiate product recalls. | [0.006970568094402552, -0.022161461412906647, 0.009369833394885063, -0.015946093946695328, -0.044349655508995056, 0.013139152899384499, -0.010512659326195717, 0.01271142903715372, 0.002738437382504344, -0.006613017525523901, -0.0011353070149198174, -0.0013332965318113565, -0.002362507861107588, -0.0011470026802271605, ... |
26 | JNJ | 2016 | In addition, business practices in the health care industry have come under increased scrutiny, particularly in the United States, by government agencies and state attorneys general, and resulting investigations and prosecutions carry the risk of significant civil and criminal penalties. | [0.018946347758173943, -0.01823698729276657, 0.028812892735004425, -0.04828803613781929, -0.014922344125807285, 0.005848991684615612, 0.010040661320090294, 0.025807788595557213, -0.012265470810234547, -0.024453556165099144, 0.004427047912031412, 0.0169343464076519, 0.004020778462290764, -0.00402400316670537, 0.00724836... |
27 | JNJ | 2016 | Further, the Company relies on global supply chains, and production and distribution processes, that are complex, are subject to increasing regulatory requirements that may affect sourcing, supply and pricing of materials used in the Company's products. These processes also are subject to lengthy regulatory approvals. | [-0.004888713825494051, -0.0170710738748312, -0.01918688789010048, -0.0053815278224647045, -0.0265331007540226, 0.01423246506601572, -0.03889944404363632, 0.012149505317211151, 0.0011137594701722264, -0.015086675994098186, -0.009639440104365349, -0.00029815241578035057, 0.0016131441807374358, -0.006689127534627914, 0.0... |
28 | JNJ | 2016 | The Company’s main corporate website address is www.jnj.com. Copies of the Company’s Quarterly Reports on Form 10-Q, Annual Report on Form 10-K and Current Reports on Form 8-K filed or furnished to the U.S. Securities and Exchange Commission (the "SEC"), and any amendments to the foregoing, will be provided without cha... | [-0.03224918246269226, -0.0013885949738323689, -0.009948808699846268, -0.027430925518274307, -0.013791942968964577, 0.007526933681219816, -0.015920644626021385, -0.003712479956448078, -0.012326071038842201, 0.006169408559799194, 0.01147204078733921, 0.01542352233082056, 0.011656868271529675, -0.005481086205691099, 0.01... |
29 | JNJ | 2016 | The Company faces a number of uncertainties and risks that are difficult to predict and many of which are outside of the Company's control. In addition to the other information in this Report and the Company’s other filings with the SEC, investors should consider carefully the factors set forth in Exhibit 99 to this Re... | [0.0021537267602980137, -0.03775867819786072, -0.009761842899024487, -0.020361335948109627, -0.03193379193544388, 0.002324478467926383, -0.034382306039333344, -0.0022536003962159157, -0.014227161183953285, 0.0031460195314139128, 0.0010253156069666147, 0.020567525178194046, -0.013067337684333324, 0.015399870462715626, 0... |
30 | JNJ | 2016 | Not applicable. | [-0.01060420647263527, -0.01894407533109188, 0.010038122534751892, -0.019523324444890022, -0.030805516988039017, 0.0015131235122680664, -0.016021501272916794, -0.012901455163955688, -0.004660321865230799, -0.03283288702368736, 0.011677133850753307, 0.0242889653891325, 0.006095279473811388, -0.001181536354124546, -0.024... |
31 | JNJ | 2016 | Item 7.MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION | [-0.02018790692090988, 0.0015844248700886965, -0.009404732845723629, -0.017919743433594704, -0.005676673725247383, -0.0018781269900500774, -0.030451033264398575, 0.004285701084882021, -0.002208639634773135, -0.00175281404517591, -0.021303191781044006, 0.029899654909968376, -0.010852096602320671, 0.02155381627380848, -0... |
32 | JNJ | 2016 | Johnson & Johnson and its subsidiaries (the Company) have approximately 127,100 employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The Company conducts business in virtually all countries of the world with the primary focus on product... | [0.0012088979128748178, 0.012746058404445648, -0.023080701008439064, -0.004781366791576147, -0.01672680862247944, 0.025198664516210556, -0.002652239054441452, 0.02832457423210144, -0.014749192632734776, 0.001744768233038485, -0.01644611544907093, 0.014608845114707947, -0.01714785024523735, -0.00836340431123972, -0.0001... |
33 | JNJ | 2016 | The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a broad range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets. These products are marketed to the general pub... | [0.009279876947402954, 0.008782260119915009, -0.012823713012039661, -0.0131128691136837, -0.024248721078038216, 0.016676880419254303, 0.01511678472161293, 0.0028058176394551992, -0.003441287437453866, -0.00985146313905716, 0.009548858739435673, 0.027368910610675812, -0.02270207554101944, -0.004565968178212643, -0.00173... |
34 | JNJ | 2016 | The Executive Committee of Johnson & Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Consumer, Pharmaceutical and Medical Devices business segments. | [-0.0015603987267240882, 0.006932981312274933, -0.026202591136097908, -0.012062622234225273, -0.033645350486040115, 0.01910393126308918, 0.00901032704859972, 0.026686880737543106, -0.01353460643440485, -0.0005507992464117706, -0.001871841261163354, 0.005696769338101149, -0.0057987249456346035, 0.012680728919804096, -0.... |
35 | JNJ | 2016 | In all of its product lines, the Company competes with companies both locally and globally, throughout the world. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, involving the development and the improvement of new and existing ... | [-0.011436018161475658, 0.00403014337643981, 0.006595958489924669, -0.016263119876384735, -0.003378970781341195, 0.02276836708188057, 0.007768717128783464, 0.011805339716374874, -0.0046456800773739815, -0.021394748240709305, -0.003693218342959881, 0.0215243361890316, -0.0009046765044331551, -0.017701530829072, -0.01060... |
36 | JNJ | 2016 | The Company manages within a strategic framework with Our Credo as the foundation. The Company believes that our strategic operating principles: being broadly based in human health care, managing the business for the long term, having a decentralized management approach, and being committed to our people and values, ar... | [-0.01013356912881136, 0.0015545445494353771, 0.009557873010635376, -0.027816615998744965, -0.02020171843469143, 0.019534433260560036, -0.008727037347853184, 0.005966310855001211, 0.006718641612678766, 0.017951268702745438, -0.014536340720951557, 0.009747590869665146, -0.00703920004889369, -0.014719516970217228, -0.000... |
37 | JNJ | 2016 | The Company is broadly based in human health care, and is committed to creating value by developing accessible, high quality, innovative products and services. New products introduced within the past five years accounted for approximately 25% of 2015 sales. In 2015, $9.0 billion, or 12.9% of sales, was invested in rese... | [-0.001118238433264196, 0.0028942639473825693, 0.0025336991529911757, -0.018281614407896996, 0.013578028418123722, 0.0017833344172686338, -0.0025499407202005386, -0.004430725239217281, -0.005531909875571728, 0.011271713301539421, 0.005908716470003128, 0.01902223378419876, -0.006253039464354515, -0.002889391500502825, -... |
38 | JNJ | 2016 | Our diverse businesses with more than 250 operating companies located in 60 countries are the key drivers of the Company’s success. Maintaining the Company’s decentralized management approach, while at the same time leveraging the extensive resources of the enterprise, positions the Company well to innovate, execute st... | [-0.02900862507522106, -0.005815408658236265, 0.000656066054943949, -0.022153936326503754, -0.01806197501718998, 0.020081892609596252, -0.011787197552621365, 0.01879175193607807, 0.010972714982926846, -0.013526933267712593, -0.01888297311961651, 0.019847320392727852, -0.025503091514110565, -0.006597312167286873, 0.0005... |
39 | JNJ | 2016 | In order to remain a leader in health care, the Company strives to maintain a purpose-driven organization and is committed to developing global business leaders who can achieve these growth objectives. Businesses are managed for the long-term in order to sustain market leadership positions and enable growth, which prov... | [-0.01846635714173317, -0.008187666535377502, 0.008207269944250584, -0.02432122454047203, -0.026542937383055687, 0.015839507803320885, -0.0032933629117906094, 0.022975126281380653, -0.0009262583334930241, 0.00342078460380435, -0.016309987753629684, 0.027104899287223816, 0.005505274515599012, -0.008710422553122044, 0.01... |
40 | JNJ | 2016 | Our Credo unifies all Johnson & Johnson employees in achieving these objectives, and provides a common set of values that serve as the foundation of the Company’s responsibilities to patients, consumers and health care professionals, employees, communities and shareholders. The Company believes that these foundational ... | [-0.013179103843867779, 0.00807163119316101, -0.016794724389910698, -0.009980418719351292, -0.02418231964111328, 0.001184034626930952, -0.0018762144027277827, 0.013270308263599873, -0.01831914857029915, 0.01811068132519722, -0.017498305067420006, 0.0006327337468974292, -0.0075569748878479, -0.02136799693107605, -0.0050... |
41 | JNJ | 2016 | In 2015, worldwide sales decreased 5.7% to $70.1 billion, compared to increases of 4.2% in 2014 and 6.1% in 2013. These sales changes consisted of the following: | [-0.02258428744971752, -0.0225591529160738, 0.009941108524799347, -0.0209127739071846, -0.010368412360548973, -0.0151441665366292, -0.008288445882499218, -0.007936548441648483, -0.01354805938899517, -0.029986705631017685, 0.01734352670609951, 0.02174224704504013, -0.003911719191819429, -0.0029817039612680674, 0.0152195... |
42 | JNJ | 2016 | In 2015, the introduction of competitive products to the Company's Hepatitis C products, OLYSIO®/SOVRIAD® (simeprevir) and INCIVO® (telaprevir), had a negative impact of 2.7% on the worldwide operational sales growth. In 2015, the impact of acquisitions and divestitures on the worldwide operational sales growth was neg... | [-0.016202351078391075, -0.008786813355982304, 0.006000994239002466, -0.027798281982541084, -0.010397729463875294, 0.01762687973678112, -0.018052907660603523, 0.011123307049274445, -0.03200530260801315, -0.00986519455909729, 0.018265921622514725, 0.006836406886577606, 0.0020352788269519806, -0.005418534856289625, 0.009... |
43 | JNJ | 2016 | In 2014, sales of the Company's Hepatitis C products, OLYSIO®/SOVRIAD® (simeprevir) and INCIVO® (telaprevir), had a positive impact of 2.8%, and the divestiture of the Ortho-Clinical Diagnostics business had a negative impact of 1.4% on the worldwide operational growth. In 2013, the acquisition of Synthes, Inc., net of... | [-0.00633639981970191, -0.007193957921117544, 0.0019669383764266968, -0.033512815833091736, -0.0076023186556994915, 0.01926102116703987, -0.023167675361037254, 0.007241599727421999, -0.03386672958731651, -0.00481185270473361, 0.026067037135362625, 0.0014913680497556925, -1.926155346154701e-05, 0.0013722627190873027, 0.... |
44 | JNJ | 2016 | Sales by U.S. companies were $35.7 billion in 2015, $34.8 billion in 2014 and $31.9 billion in 2013. This represents increases of 2.6% in 2015, 9.0% in 2014 and 7.0% in 2013. Sales by international companies were $34.4 billion in 2015, $39.5 billion in 2014 and $39.4 billion in 2013. This represents a decrease of 13.1%... | [-0.011439910158514977, -0.030372772365808487, 0.009078000672161579, -0.019709724932909012, -0.004404302686452866, -0.019033102318644524, -0.01840660162270069, -0.016664929687976837, -0.00201263464987278, -0.015599877573549747, 0.022691870108246803, 0.02628798596560955, -0.004069124814122915, 0.004316592589020729, 0.00... |
45 | JNJ | 2016 | The five-year compound annual growth rates for worldwide, U.S. and international sales were 2.6%, 3.9% and 1.4%, respectively. The ten-year compound annual growth rates for worldwide, U.S. and international sales were 3.3%, 2.3% and 4.5%, respectively. | [-0.016665956005454063, -0.02490181475877762, 0.01844003237783909, -0.035377927124500275, -0.0001546853600302711, -0.014684689231216908, -0.006571851670742035, -0.00024846778251230717, -0.01594078727066517, -0.029188085347414017, 0.016821350902318954, 0.035041242837905884, 0.0049272701144218445, 0.0033037313260138035, ... |
46 | JNJ | 2016 | Sales by companies in Europe experienced a decline of 15.6% as compared to the prior year, including operational growth of 1.1%, offset by a negative currency impact of 16.7%. Sales by companies in the Western Hemisphere (excluding the U.S.) experienced a decline of 15.6% as compared to the prior year, including operat... | [-0.02068064734339714, -0.028942447155714035, 0.007209466770291328, -0.02902088314294815, -0.006127720233052969, 0.005398930050432682, -0.007889235392212868, -0.0028710411861538887, -0.009712845087051392, -0.04057694599032402, 0.0008644170593470335, 0.03341323137283325, 0.007379408925771713, 0.003709313226863742, 0.018... |
47 | JNJ | 2016 | 2015 results benefited from the inclusion of a 53rd week. (See Note 1 to the Consolidated Financial Statements for Annual Closing Date details). The Company estimated that the fiscal year 2015 growth rate was enhanced by approximately 1.0%. While the additional week added a few days to sales, it also added a full week'... | [-0.022472042590379715, -0.006138259544968605, 0.0025336788967251778, -0.02121533825993538, -0.0023225389886647463, -0.014715607278048992, -0.013891316950321198, -0.0036687671672552824, -0.04226852208375931, -0.007249699905514717, 0.00492885010316968, 0.027120498940348625, 0.008756394498050213, 0.01806681975722313, -0.... |
48 | JNJ | 2016 | In 2015 and 2014, the Company had one wholesaler distributing products for all three segments that represented approximately 12.5% and 11.0%, respectively, of the total consolidated revenues. In 2013, the Company did not have a customer that represented 10% or more of total consolidated revenues. | [-0.012961717322468758, -0.02033890038728714, -0.0014244560152292252, -0.0011595571413636208, -0.0016077193431556225, 0.0030804902780801058, -0.01297504547983408, 0.007277220953255892, 0.006517511326819658, -0.017313389107584953, 0.012535213492810726, 0.0383053719997406, -0.003625282319262624, -0.00284557999111712, 0.0... |
49 | JNJ | 2016 | U.S. Health Care Reform | [-0.021391773596405983, 0.0024657389149069786, 0.022938644513487816, -0.01640740968286991, -0.001289885607548058, 0.004759603179991245, -0.016856929287314415, -0.012441074475646019, -0.005572702270001173, -0.010001777671277523, 0.028980696573853493, 0.008011998608708382, 0.00799216702580452, 0.0016898245085030794, -0.0... |
50 | JNJ | 2016 | On July 28, 2014, the Internal Revenue Service issued final regulations for the Branded Prescription Drug Fee, an annual non-tax deductible fee imposed on entities engaged in the business of manufacturing or importing branded prescription drugs (covered entities), enacted by Section 9008 of the Patient Protection and A... | [-0.010280660353600979, -0.00637775519862771, -0.016012948006391525, -0.04663419723510742, -0.0010977966012433171, -0.005983117036521435, -0.006785770878195763, 0.000578997831325978, -0.01603970304131508, 0.0028477495070546865, 0.019972708076238632, 0.0031771722715348005, 0.008902770467102528, 0.009625159204006195, -0.... |
51 | JNJ | 2016 | Consumer segment sales in 2015 were $13.5 billion, a decrease of 6.8% from 2014, which included 2.7% operational growth offset by a negative currency impact of 9.5%. U.S. Consumer segment sales were $5.2 billion, an increase of 2.5%. International sales were $8.3 billion, a decrease of 11.9%, which included 2.7% operat... | [-0.011514206416904926, -0.010422230698168278, 0.017122698947787285, -0.021451832726597786, -0.005233730189502239, -0.01802729442715645, 0.004917121957987547, -0.0007798096630722284, -0.006971845868974924, -0.023028412833809853, 0.005676336120814085, 0.04510053992271423, -0.023894241079688072, -0.017898065969347954, 0.... |
52 | JNJ | 2016 | The Over-the-Counter (OTC) franchise sales of $4.0 billion decreased 3.2% as compared to the prior year, which included 8.1% operational growth and a negative currency impact of 11.3%. Operational growth was primarily driven by analgesics, upper respiratory, including ZYRTEC®, and digestive health products. | [0.007156013045459986, 0.0010325056500732899, -0.0012824275763705373, -0.03201692923903465, -0.0009138558525592089, 0.011302865110337734, 0.0064962864853441715, -0.017947252839803696, 0.012103961780667305, -0.008832256309688091, 0.025123462080955505, 0.02322506532073021, -0.014500519260764122, -0.01138364803045988, 0.0... |
53 | JNJ | 2016 | McNEIL-PPC, Inc. (now Johnson & Johnson Consumer Inc.) (McNEIL-PPC) continues to operate under a consent decree, signed in 2011 with the U.S. Food and Drug Administration (FDA), which governs certain McNeil Consumer Healthcare manufacturing operations and requires McNEIL-PPC to remediate the facilities it operates in L... | [0.007690227124840021, 0.013032984919846058, -0.011075599119067192, -0.02148248255252838, -0.01611882820725441, 0.02713870070874691, 0.005346240475773811, 0.013088710606098175, -0.02079983614385128, -0.014126612804830074, 0.03505183383822441, 0.018097110092639923, -0.00043753840145654976, -0.005422864109277725, 0.01971... |
54 | JNJ | 2016 | The Skin Care franchise sales of $3.5 billion decreased 6.0% as compared to the prior year, which included 1.3% operational growth and a negative currency impact of 7.3%. Operational growth was primarily due to sales growth of NEUTROGENA® and AVEENO® products partially offset by lower sales in China. | [-0.0060678268782794476, -0.008136553689837456, 0.014151674695312977, -0.022505642846226692, 0.004763342905789614, -0.0016824878985062242, -0.0037355676759034395, -0.020753154531121254, -0.006617950275540352, -0.019040195271372795, 0.03586672246456146, 0.0359194278717041, 0.008663618005812168, -0.007807138841599226, 0.... |
55 | JNJ | 2016 | The Baby Care franchise sales were $2.0 billion in 2015, a decrease of 8.7% compared to the prior year, which included 1.2% operational growth and a negative currency impact of 9.9%. Operational growth was primarily due to new product launches partially offset by competition in China. | [-0.006304696202278137, -0.013672677800059319, -0.00497069675475359, -0.03272049501538277, -0.013189959339797497, -0.010000103153288364, 0.010228415951132774, -0.0028033556882292032, -0.01962185837328434, -0.02335314266383648, 0.015903621912002563, 0.05080287158489227, 0.00948476791381836, -0.011454781517386436, 0.0263... |
56 | JNJ | 2016 | The Oral Care franchise sales were $1.6 billion in 2015, a decrease of 4.1% as compared to the prior year, which included 5.2% operational growth and a negative currency impact of 9.3%. Operational growth was driven by increased sales of LISTERINE® products, attributable to geographical expansion of new products and s... | [-0.005564967170357704, -0.0012577346060425043, 0.016724208369851112, -0.030374495312571526, 0.007867150940001011, 0.001989581622183323, 0.016072953119874, -0.001137252664193511, 0.005281671416014433, -0.03172910585999489, 0.014887670986354351, 0.026128318160772324, -0.023523300886154175, -0.014158266596496105, 0.01232... |
57 | JNJ | 2016 | The Women’s Health franchise sales were $1.2 billion in 2015, a decrease of 7.8% as compared to the prior year, which included 7.6% operational growth and a negative currency impact of 15.4%. Operational growth outside the U.S. was driven by new product launches and successful marketing campaigns. | [-0.02071487158536911, -0.009411756880581379, -0.003113663988187909, -0.02059907466173172, 0.011470378376543522, -0.01685495860874653, 0.007327403407543898, -0.01736961305141449, 0.004808809608221054, -0.03679784759879112, 0.01639176905155182, 0.03347831964492798, 0.006082581356167793, 0.0019460399635136127, 0.01332957... |
58 | JNJ | 2016 | The Wound Care/Other franchise sales were $1.2 billion in 2015, a decrease of 18.5% from 2014, primarily due to the SPLENDA® and BENECOL® divestitures. | [-0.0008131447830237448, -0.00982913188636303, 0.0030433780048042536, -0.018330002203583717, -0.0011589077766984701, -0.002869043732061982, 0.01874176412820816, -0.004230511374771595, 0.003785543842241168, -0.004964375402778387, 0.015474241226911545, 0.04901283234357834, -0.00897904485464096, 0.007537881378084421, 0.02... |
59 | JNJ | 2016 | Consumer segment sales in 2014 were $14.5 billion, a decrease of 1.4% from 2013, which included 1.0% operational growth offset by a negative currency impact of 2.4%. U.S. Consumer segment sales were $5.1 billion, a decrease of 1.3%. International sales were $9.4 billion, a decrease of 1.4%, which included 2.3% operatio... | [-0.006024462170898914, -0.01864699460566044, 0.014108840376138687, -0.020358309149742126, -0.007143154740333557, -0.021600596606731415, 0.009596039541065693, -0.007910077460110188, -0.002947264350950718, -0.026037339121103287, 0.0029282497707754374, 0.04751117154955864, -0.022931618615984917, -0.02636692486703396, 0.0... |
60 | JNJ | 2016 | Pharmaceutical segment sales in 2015 were $31.4 billion, a decrease of 2.7% from 2014, which included operational growth of 4.2% offset by a negative currency impact of 6.9%. U.S. sales were $18.3 billion, an increase of 5.2%. International sales were $13.1 billion, a decrease of 12.0%, which included 3.0% operational ... | [0.004060433711856604, -0.008395044133067131, -0.003926609177142382, -0.023683687672019005, -0.010033579543232918, 0.01249464601278305, 6.165926606627181e-05, 0.0017233995022252202, -0.018839890137314796, -0.01248811837285757, 0.020850522443652153, 0.028253307566046715, -0.007455008570104837, -0.009478697553277016, 0.0... |
61 | JNJ | 2016 | * Prior year amounts have been reclassified to conform to current year presentation. | [-0.015488499775528908, -0.023546619340777397, -0.0009472133824601769, -0.02076663263142109, -0.0036703518126159906, 0.012003907933831215, -0.0169233325868845, -0.006549624260514975, -0.020638521760702133, -0.0010368904331699014, 0.023264776915311813, 0.014040856622159481, -0.012228100560605526, 0.008487287908792496, -... |
62 | JNJ | 2016 | Immunology products achieved sales of $10.4 billion in 2015, representing an increase of 2.1% as compared to the prior year. Immunology products growth of 2.1% included operational growth of 6.9% and a negative currency impact of 4.8%. The increased sales of STELARA® (ustekinumab) and SIMPONI®/SIMPONI ARIA® (golimumab)... | [-0.01569068804383278, -0.007542587351053953, 0.002071578986942768, -0.029512183740735054, 0.0033072864171117544, 0.0017260415479540825, -0.01424272172152996, -0.015677524730563164, -0.01963968761265278, -0.02552369423210621, 0.028564423322677612, -0.00014942434791009873, 0.008450857363641262, -0.006851512938737869, 0.... |
63 | JNJ | 2016 | Additional biosimilar competition will likely result in a further reduction in REMICADE® sales in markets outside the United States. The timing of the possible introduction of a biosimilar version of REMICADE® in the United States is subject to enforcement of patent rights, approval by the FDA and compliance with the 1... | [-0.03485271707177162, -0.00298185832798481, -0.0008837560308165848, -0.015619569458067417, 0.02316095307469368, 0.0036135802511125803, -0.019940154626965523, -0.005548024084419012, -0.021707667037844658, 0.005822970066219568, 0.02364538237452507, -0.006405594293028116, 0.009374359622597694, -0.027547001838684082, -0.0... |
64 | JNJ | 2016 | Infectious disease products sales were $3.7 billion, a decline of 34.7% from 2014, which included an operational decrease of 27.6% and a negative currency impact of 7.1%. Competitive products to the Company's Hepatitis C products, OLYSIO®/SOVRIAD® (simeprevir) and INCIVO® (telaprevir), had a significant negative impact... | [-0.016355937346816063, -0.0031410532537847757, -8.535919187124819e-05, -0.01430814154446125, 0.0013599670492112637, 0.015047989785671234, -0.015497183427214622, -0.009149019606411457, -0.018601905554533005, -0.015933165326714516, 0.021984070539474487, 0.013938217423856258, -0.0022624831181019545, 5.805870273434266e-07... |
65 | JNJ | 2016 | Neuroscience products sales were $6.3 billion, a decrease of 3.5% from 2014, which included an operational growth of 5.0% and a negative currency impact of 8.5%. The U.S. sales growth of CONCERTA®/methylphenidate was primarily due to a therapeutic equivalence reclassification of generic competitors by the FDA in Novemb... | [-0.004790799226611853, 0.010191336274147034, 0.035673029720783234, -0.025434788316488266, -0.003969998098909855, 0.005745608825236559, -0.013856465928256512, -0.010419150814414024, -0.005236377008259296, -0.013709056191146374, 0.014928532764315605, 0.029589049518108368, -0.002609813120216131, 0.0017906868597492576, 0.... |
66 | JNJ | 2016 | Oncology products achieved sales of $4.7 billion in 2015, representing an increase of 5.3% as compared to the prior year. Oncology products growth of 5.3% included operational growth of 17.7% and a negative currency impact of 12.4%. Contributors to the growth were strong sales of IMBRUVICA® (ibrutinib) due to the appro... | [-0.015750423073768616, -0.02420659363269806, 0.00821087695658207, -0.025910736992955208, 0.01598280668258667, 0.004331366624683142, -0.013491141609847546, -0.006997319404035807, -0.011380326934158802, -0.0058386302553117275, 0.012161392718553543, -0.006803666707128286, 0.0021075874101370573, -0.0015492220409214497, -0... |
67 | JNJ | 2016 | Cardiovascular/Metabolism/Other products achieved sales of $6.4 billion in 2015, representing an increase of 15.1% as compared to the prior year due to strong sales of XARELTO®(rivaroxaban) and INVOKANA®/INVOKAMET® (canagliflozin). PROCRIT®/EPREX® (Epoetin alfa) sales were impacted by competition. | [-0.013887317851185799, -0.024864042177796364, 0.009142919443547726, -0.008614313788712025, 0.006281270645558834, 0.018938438966870308, -0.011537959799170494, -0.006189906504005194, -0.01942136324942112, 0.004215793218463659, 0.01606700010597706, 0.02068740501999855, -0.007100283168256283, -0.01861213892698288, -0.0018... |
68 | JNJ | 2016 | The Pharmaceutical segment achieved sales of $32.3 billion in 2014, representing an increase of 14.9% over the prior year, with strong operational growth of 16.5% and a negative currency impact of 1.6%. U.S. sales were $17.4 billion, an increase of 25.0%. International sales were $14.9 billion, an increase of 5.0%, whi... | [0.006913361139595509, -0.008099253289401531, -0.0029810203704982996, -0.030364055186510086, -0.009962798096239567, 0.00469469977542758, 0.001434310688637197, -0.0020720534957945347, -0.015612076036632061, -0.015507821924984455, 0.028383223339915276, 0.027627380564808846, -0.00785816553980112, -0.004192976281046867, 0.... |
69 | JNJ | 2016 | The Medical Devices segment sales in 2015 were $25.1 billion, a decrease of 8.7% from 2014, which included an operational decline of 1.4% and a negative currency impact of 7.3%. U.S. sales were $12.1 billion, a decrease of 1.0% as compared to the prior year. International sales were $13.0 billion, a decrease of 14.8% a... | [-0.015409170649945736, 0.0007454089354723692, 0.017354773357510567, -0.027679435908794403, 0.008469855412840843, -0.0012524814810603857, -0.005058566108345985, -0.0026833098381757736, -0.011310434900224209, -0.01524055190384388, 0.012743695639073849, 0.043062664568424225, -0.010233868844807148, 0.010940770618617535, 0... |
70 | JNJ | 2016 | * Prior year amounts have been reclassified to conform to current year presentation. | [-0.013071759603917599, -0.02488097921013832, -0.003618645714595914, -0.019945593550801277, -0.0024708814453333616, 0.014818912371993065, -0.013039877638220787, -0.003558069234713912, -0.025340085849165916, 0.0008632143726572394, 0.025059521198272705, 0.013581877574324608, -0.014053735882043839, 0.005802586209028959, -... |
71 | JNJ | 2016 | The Orthopaedics franchise sales were $9.3 billion in 2015, a decrease of 4.3% from 2014, which included operational growth of 1.7% and a negative currency impact of 6.0%. Operational growth in the U.S. and Europe regions was primarily driven by sales of the hip primary stem platform, the ATTUNE® Knee System, trauma TF... | [-0.010028994642198086, -0.016633454710245132, 0.002941926708444953, -0.047626156359910965, 0.013803916051983833, -0.0007049054256640375, -0.021036427468061447, -0.005298773292452097, 0.008415893651545048, -0.014174136333167553, 0.01143715251237154, 0.013341140933334827, 0.005721881985664368, -0.010432270355522633, 0.0... |
72 | JNJ | 2016 | The Surgery franchise sales were $9.2 billion in 2015, a decrease of 5.1% from 2014, which included operational growth of 2.7% and a negative currency impact of 7.8%. Operational growth in Advanced Surgery was driven by endocutter, biosurgical and energy products, primarily attributable to market growth, increased pene... | [-0.01373363845050335, -0.008783061988651752, 0.011558079160749912, -0.023991769179701805, -0.0010591538157314062, 0.0035361256450414658, -0.0075774118304252625, -0.007611089386045933, -0.002919829450547695, -0.01817231811583042, 0.0195598267018795, 0.032599709928035736, -0.00487648556008935, -0.006129284389317036, 0.0... |
73 | JNJ | 2016 | The Vision Care franchise sales were $2.6 billion in 2015, a decrease of 7.5% from 2014, which included operational growth of 1.7% and a negative currency impact of 9.2%. Operational growth in all the major regions was primarily driven by new product launches partially offset by lower price. | [-0.0019437945447862148, -0.015146620571613312, 0.015706641599535942, -0.025513524189591408, 0.005183452274650335, 0.007488655857741833, -0.0018900716677308083, -0.02026495337486267, -0.00892126839607954, -0.02198408916592598, -0.0016287826001644135, 0.03967034071683884, 0.003584787016734481, -0.02118963934481144, 0.01... |
74 | JNJ | 2016 | The Cardiovascular franchise sales were $2.0 billion, a decrease of 7.8% from 2014, which represented an operational decline of 0.1% and a negative currency impact of 7.7%. Strong operational growth in the electrophysiology business was driven by market growth and the success of the THERMOCOOL® SMARTTOUCH® Catheter and... | [-0.030343227088451385, 0.0010170351015403867, 0.011311578564345837, -0.03514980897307396, 0.0006830582278780639, 0.006776877678930759, 0.007995305582880974, -0.005931026767939329, -0.0087068947032094, -0.018783261999487877, 0.0059075308963656425, 0.03531092405319214, -0.01709156110882759, -0.01203659363090992, 0.01421... |
75 | JNJ | 2016 | The Diabetes Care franchise sales were $1.9 billion, a decrease of 10.0% from 2014, which represented an operational decline of 0.7% and a negative currency impact of 9.3%. The operational decline was primarily due to lower price partially offset by the success of the ANIMAS® VIBE® products. | [-0.021509060636162758, -0.026843413710594177, 0.015276847407221794, -0.031187478452920914, 0.006420368794351816, 0.0061926026828587055, -0.004849111661314964, -0.019845377653837204, -0.0008607255294919014, -0.010926180519163609, -0.004046977963298559, 0.03834396228194237, 0.004469500854611397, -0.008780555799603462, 0... |
76 | JNJ | 2016 | On June 30, 2014, the Company divested the Ortho-Clinical Diagnostics business (the Diagnostics Franchise) to The Carlyle Group. For additional details see Note 20 to the Consolidated Financial Statements. | [-0.003128036158159375, 0.0039429026655852795, -0.0004287906631361693, -0.04132162034511566, -0.01461502630263567, 0.029072334989905357, -0.005743494722992182, -0.007399513851851225, -0.00047438047477044165, -0.0010670480551198125, 0.023486556485295296, 0.02604944445192814, 0.005529921036213636, 0.009252678602933884, 0... |
77 | JNJ | 2016 | The Medical Devices segment sales in 2014 were $27.5 billion, a decrease of 3.4% from 2013, which included an operational decline of 1.6% and a negative currency impact of 1.8%. U.S. sales were $12.3 billion, a decrease of 4.3% as compared to the prior year. International sales were $15.3 billion, a decline of 2.7% as ... | [-0.013386323116719723, -0.0020121438428759575, 0.016406958922743797, -0.02788279578089714, -0.0012150314869359136, 0.0015732479514554143, -0.009629891254007816, -0.0050505297258496284, -0.01521935872733593, -0.014212480746209621, 0.014703011140227318, 0.041075486689805984, -0.0061122700572013855, 0.0025268783792853355... |
78 | JNJ | 2016 | Consolidated earnings before provision for taxes on income decreased to $19.2 billion as compared to $20.6 billion in 2014, a decrease of 6.6%. The decrease was primarily attributable to significantly lower sales of OLYSIO®/SOVRIAD® (simeprevir), negative currency impacts, a restructuring charge of $0.6 billion and hig... | [-0.006881081499159336, 0.00046524350182153285, 0.004060307051986456, -0.019966525956988335, -0.0015284777618944645, 0.005681749898940325, -0.002480740426108241, -0.008777230978012085, -0.027872735634446144, -0.01794307306408882, 0.02720271795988083, 0.019711919128894806, -0.006505871657282114, 0.005001681856811047, 0.... |
79 | JNJ | 2016 | Consolidated earnings before provision for taxes on income increased to $20.6 billion in 2014 as compared to $15.5 billion in 2013, an increase of 32.9%. Earnings before provision for taxes on income were favorable due to strong sales volume growth, particularly sales of OLYSIO®/SOVRIAD® (simeprevir), positive mix from... | [-0.003969465848058462, 0.0003159226616844535, -0.00803186185657978, -0.027401261031627655, -0.0033372053876519203, 0.0005380849470384419, 0.000790740130469203, -0.004825755022466183, -0.01765681989490986, -0.02065715193748474, 0.022675074636936188, 0.003979422617703676, -0.006876866798847914, 0.0009608363616280258, 0.... |
80 | JNJ | 2016 | As a percent to sales, consolidated earnings before provision for taxes on income in 2015 was 27.4% versus 27.7% in 2014. | [-0.00925381202250719, -0.009696881286799908, 0.0031521194614470005, -0.018254442140460014, 0.0041173771023750305, -0.020077355206012726, -0.01110837236046791, -0.019735559821128845, -0.014975732192397118, -0.012095783837139606, 0.023723179474473, 0.027520913630723953, 0.012178068049252033, -0.005607987754046917, 0.006... |
81 | JNJ | 2016 | In 2015, cost of products sold as a percent to sales increased slightly as compared to the prior year. Favorable mix between the segments was offset by $81 million associated with the restructuring activity in the Medical Devices segment, negative transactional currency and lower sales of OLYSIO®/SOVRIAD® (simeprevir) ... | [0.011842083185911179, 0.00440635671839118, -0.00013685901649296284, -0.017020896077156067, -0.00539039820432663, 0.014186318963766098, -0.003821976948529482, 0.0048060184344649315, -0.017208972945809364, -0.01029045507311821, 0.01970769837498665, 0.02082272246479988, -0.009591885842382908, 0.005031038541346788, 0.0084... |
82 | JNJ | 2016 | In 2014, cost of products sold as a percent to sales decreased compared to the prior year. This was primarily the result of positive mix from higher sales of higher margin products in the Pharmaceutical business, divestitures of lower margin businesses and cost improvements across many of the businesses. This was parti... | [6.925078923813999e-05, 0.0026823803782463074, 0.0006714338669553399, -0.01492336206138134, -0.0139034204185009, 0.011534739285707474, 0.0007938939961604774, -0.004351528827100992, -0.015097825787961483, -0.011179101653397083, 0.017634261399507523, 0.020667245611548424, -0.0013059619814157486, -0.001322737312875688, 0.... |
83 | JNJ | 2016 | Research and development activities represent a significant part of the Company's business. These expenditures relate to the processes of discovering, testing and developing new products, upfront payments and milestones, improving existing products, as well as ensuring product efficacy and regulatory compliance prior t... | [-0.0018290197476744652, -0.0018939360743388534, 0.0029520734678953886, -0.023681504651904106, -0.0026469663716852665, 0.008159992285072803, 0.020253919064998627, 0.002478183712810278, -0.006144337821751833, -0.005014792550355196, 0.008380708284676075, 0.02749858982861042, -0.012165334075689316, -0.0015295927878469229,... |
84 | JNJ | 2016 | In-Process Research and Development (IPR&D): In 2015, the Company recorded an IPR&D charge of $0.2 billion primarily for the discontinuation of certain development projects related to Covagen. In 2014, the Company recorded an IPR&D charge of $0.2 billion for the impairment of various IPR&D projects related to RespiVert... | [-0.018672261387109756, -0.009585543535649776, 0.005942093674093485, -0.015746716409921646, 0.016730885952711105, 0.018699225038290024, 0.0005755033926106989, -0.008850786834955215, -0.003774897661060095, -0.0032524787820875645, 0.020681045949459076, 0.02103157341480255, 0.005500565283000469, -0.007805949077010155, 0.0... |
85 | JNJ | 2016 | Other (Income) Expense, Net: Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson & Johnson Innovation - JJDC, Inc. (formerly Johnson & Johnson Development Corporation), gains and losses on di... | [-0.017430201172828674, -0.0029543854761868715, -0.0019365021726116538, -0.0045190658420324326, -0.006258720997720957, 0.011057074181735516, 0.0074768164195120335, 0.0025034884456545115, -0.01580158807337284, -0.008674722164869308, 0.029476556926965714, 0.025680946186184883, -0.007658521179109812, 0.0029409260023385286... |
86 | JNJ | 2016 | The change in other (income) expense, net for the fiscal year 2014 was a favorable change of $2.6 billion as compared to the prior year. The fiscal year 2014 included higher net gains on divestitures of $2.3 billion, primarily the divestiture of the Ortho-Clinical Diagnostics business, lower litigation expense of $1.0 ... | [-0.006790556479245424, 0.0047550746239721775, 0.00738030718639493, -0.024102263152599335, -0.0028004725463688374, 0.0007270781788975, -0.00486291479319334, -0.007569027133285999, -0.013028432615101337, -0.009152928367257118, 0.025355903431773186, 0.014437093399465084, -0.0009756159270182252, -3.936058419640176e-06, 0.... |
87 | JNJ | 2016 | Interest (Income) Expense: Interest income in 2015 increased by $61 million as compared to 2014 due to a higher average balance of cash, cash equivalents and marketable securities and higher interest rates. Cash, cash equivalents and marketable securities totaled $38.4 billion at the end of 2015, and averaged $35.7 bi... | [-0.03378214314579964, -0.005608465988188982, 0.02180340513586998, -0.03851059079170227, 0.00033144294866360724, 0.0020506365690380335, -0.008432401344180107, -0.021645789965987206, -0.010527366772294044, -0.030551034957170486, 0.02144877053797245, 0.021566981449723244, -0.01844095252454281, 0.013397272676229477, -0.00... |
88 | JNJ | 2016 | Interest expense in 2015 increased slightly as compared to 2014. The average debt balance was $19.3 billion in 2015 versus $18.5 billion in 2014. The total debt balance at the end of 2015 was $19.9 billion as compared to $18.8 billion at the end of 2014. The higher debt balance of approximately $1.1 billion was an incr... | [-0.0383773073554039, 0.004184352234005928, 0.004200310911983252, -0.047799281775951385, -0.002732116961851716, -0.014452132396399975, -0.019380157813429832, 0.0034789808560162783, -0.00373431877233088, -0.006233439780771732, 0.01862690970301628, 0.02139732800424099, -0.02778077870607376, 0.009524108842015266, 0.005087... |
89 | JNJ | 2016 | Interest income in 2014 was comparable to the prior year. A higher balance in cash, cash equivalents and marketable securities was offset by lower interest rates. Cash, cash equivalents and marketable securities totaled $33.1 billion at the end of | [-0.03998042270541191, -0.02176911011338234, 0.004373658448457718, -0.02581322379410267, -0.0023771971464157104, 0.002673147013410926, -0.014691909775137901, -0.024034326896071434, -0.011089320294559002, -0.029690967872738838, 0.021653929725289345, 0.015843713656067848, -0.019990211352705956, 0.00597978662699461, 0.011... |
90 | JNJ | 2016 | 2014, and averaged $31.1 billion as compared to the $25.2 billion average cash balance in 2013. The increase in the year-end cash balance was primarily due to cash generated from operating activities. | [-0.024639226496219635, -0.021352311596274376, 0.005543509963899851, -0.03165552765130997, -0.010202080942690372, -0.015638133510947227, -0.014740553684532642, -0.014866973273456097, -0.017597641795873642, -0.018697494640946388, 0.028318043798208237, 0.02573907934129238, -0.02546095661818981, 0.013084453530609608, 0.00... |
91 | JNJ | 2016 | Interest expense in 2014 increased by $51 million as compared to 2013 due to a higher average debt balance. The average debt balance was $18.5 billion in 2014 versus $17.2 billion in 2013. The total debt balance at the end of 2014 was $18.8 billion as compared to $18.2 billion at the end of 2013. The higher debt balanc... | [-0.04094831272959709, -0.011479692533612251, 0.008711174130439758, -0.05598844960331917, -0.010398038662970066, -0.009599675424396992, -0.018993321806192398, -0.00019144221732858568, -0.010520368814468384, -0.017383718863129616, 0.01305710431188345, 0.01863277144730091, -0.017628377303481102, -0.013997112400829792, 0.... |
92 | JNJ | 2016 | (1) See Note 18 to the Consolidated Financial Statements for more details. | [-0.02947908267378807, -0.01839556358754635, 0.003928620368242264, -0.015432261861860752, 0.008081733249127865, 0.009999540634453297, -0.018626470118761063, -0.004826590418815613, 0.005689283367246389, -0.011192558333277702, 0.010910339653491974, 0.0451037660241127, -0.014867822639644146, 0.0036624360363930464, -0.0182... |
93 | JNJ | 2016 | (2) Amounts not allocated to segments include interest (income) expense, noncontrolling interests, and general corporate (income) expense. | [-0.0158227626234293, -0.01821134425699711, 0.012309402227401733, -0.03045755624771118, -0.004337990190833807, 0.002657137345522642, -0.016429387032985687, -0.0032179481349885464, 0.0009462694870308042, -0.01706128567457199, 0.016239816322922707, 0.03930414840579033, 0.008176779374480247, 0.007652302738279104, 0.005342... |
94 | JNJ | 2016 | Consumer Segment: In 2015, the Consumer segment income before tax as a percent to sales was 13.2%, versus 13.4% in 2014, primarily due to lower divestiture gains in 2015 versus 2014. In 2015, the Consumer segment tax included a gain of $0.3 billion from divestitures, primarily the divestiture of the SPLENDA® brand. In ... | [0.006289500743150711, -0.010936541482806206, 0.006216942332684994, -0.023442983627319336, -0.012367921881377697, -0.012981371022760868, 0.016464177519083023, 0.008100164122879505, -0.013133084401488304, -0.02245355024933815, 0.022506320849061012, 0.041820067912340164, -0.024155376479029655, -0.0008731753332540393, 0.0... |
95 | JNJ | 2016 | Pharmaceutical Segment: In 2015, the Pharmaceutical segment income before tax as a percent to sales was 37.3% versus 36.2% in 2014. The favorable income before tax was primarily due to higher gains recognized in 2015 partially offset by a sales decline of OLYSIO®/SOVRIAD®(simeprevir), increased investment spending and ... | [0.011171027086675167, -0.011745423078536987, -0.0055260928347706795, -0.019753966480493546, -0.009573278948664665, 0.010200493969023228, -0.001445070025511086, 0.0031344236340373755, -0.011098401620984077, -0.011454924009740353, 0.036021940410137177, 0.026210978627204895, -0.003987765870988369, 0.0033060824498534203, ... |
96 | JNJ | 2016 | In 2014, the Pharmaceutical segment income before tax as a percent to sales was 36.2% versus 32.6% in 2013. The favorable income before tax was attributable to strong sales volume growth, particularly sales of OLYSIO®/SOVRIAD® (simeprevir), positive sales mix of higher margin products and cost containment initiatives r... | [0.006258048582822084, -0.013101334683597088, -0.0058523728512227535, -0.024167640134692192, -0.0034050168469548225, 0.008785209618508816, -0.003996904473751783, 0.0045887925662100315, -0.012642455287277699, -0.010547571815550327, 0.03325212001800537, 0.020243890583515167, -0.004535588901489973, 0.003830644069239497, 0... |
97 | JNJ | 2016 | Medical Devices Segment: In 2015, the Medical Devices segment income before tax as a percent to sales was 27.2% versus 28.9% in 2014 primarily due to a restructuring charge of $0.6 billion, an intangible asset write-down of $0.3 billion related to Acclarent, and lower gains of $0.5 billion on divestitures as compared t... | [0.00015561182226520032, 0.014128724113106728, 0.017700741067528725, -0.026903003454208374, 0.012342715635895729, 0.006124881561845541, -0.006217833608388901, 0.007223708555102348, -0.013610848225653172, -0.006599601358175278, 0.02447296865284443, 0.04506850615143776, -0.013942820020020008, 0.018377965316176414, 0.0188... |
98 | JNJ | 2016 | In 2014, Medical Devices segment income before tax as a percent to sales was 28.9% versus 18.5% in 2013. The favorable income before tax was attributable to the net gain of $1.9 billion on the divestiture of the Ortho-Clinical Diagnostics business in 2014 and lower litigation expense of $1.1 billion as compared to 2013... | [-0.0026180094573646784, -0.0007271336507983506, 0.002637705998495221, -0.028573233634233475, -0.0005428881850093603, -0.007918042130768299, -0.002289732452481985, 0.001874461886473, -0.010826577432453632, -0.005863028112798929, 0.023018786683678627, 0.03731853514909744, -0.0016988336574286222, 0.01016345713287592, 0.0... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.